Newer Antibiotics for Community Acquired Pneumonia

Community-acquired pneumonia (CAP) is the leading cause of death worldwide, with a significant impact on morbidity rates. Increasing antibiotic resistance amongst the common bacterial pathogens associated with CAP,
especially staphylococci and
Streptococcus pneumoniae, has made the empiric treatment of this infection
increasingly problematic.
Approximately 6% of CAP are caused by antibiotic-resistant pathogens.

During recent decades, the number of patients requiring intensive care management due to severe community-acquired pneumonia (SCAP) has increased globally, especially among the elderly, patients with comorbidities
and the immunocompromised.


With advent of molecular diagnostic techniques, following changing trends have been reported recently in United States and Spain.

The need to cover the changing pathogens in CAP is never greater. Following table summarizes the newer antibiotics which are currently undergoing phase 3 trials.

Pantoprazole reduces GI bleeding in intubated patients without improving mortality.Read more